Research Watch
Cancer Discov January 15 2021 DOI:10.1158/2159-8290.CD-RW2021-003
FBXO44 bound H3K9me3 at replication forks, recruiting a complex to repress repetitive elements.
FBXO44 bound H3K9me3 at replication forks, recruiting a complex to repress repetitive elements.
B-cell expression of the EBV protein LMP1 elicited T-cell responses against tumor-associated antigens.
Sotigalimab had manageable toxicity and an early efficacy signal in a phase Ib pancreatic cancer trial.
Structural and biochemical analyses uncovered the substrate binding and transport mechanisms of MCT1.
Chromothripsis (chromosome shattering) produced extrachromosomal DNA with amplified oncogenes.
In a phase I trial, the DARPin MG0250 had an expected safety profile and early signs of efficacy.
Combination approach uncovers novel treatment avenues.
With longer follow-up, PFS increases; early OS results seem promising.
KO-539 induced complete remissions in two patients with relapsed/refractory disease.
Patients with cancer and controls developed IgGs at the same rate and in the same time span.
NCI initiative yields mechanistic explanations for nearly one quarter of standout responses.
PARP inhibitor treatment increased tumor infiltration by immunosuppressive macrophages in vivo.
IFNγ signaling in melanoma cells caused tryptophan depletion, resulting in frameshifted polypeptides.
Histone 1 (H1) deficiency altered chromatin architecture to enable transcription of stemness genes.
Mutations promoting myeloproliferative neoplasms might be established decades before diagnosis.
Patients hesitant to return to health centers; missed exams mean more advanced disease.
Strategies include broadening eligibility criteria and reaching out to minority, low-income patients.
In mice, obesity remodeled TME metabolism, reducing infiltration by CD8+ T cells and antitumor immunity.
Injection of DNA-barcoded cancer cell lines into mice revealed their metastatic characteristics.
Some anti–PD-1–refractory patients responded to anti–PD-1 after fecal microbiota transplantation.
The presence of memory stem-like CD8+ tumor-infiltrating lymphocytes was associated with response.
Prior work in oncology underpins the record-breaking speed of development.
Microsatellite insertions and deletions generated antigenic mutant proteins shared among patients.
KRAS/LKB1-comutant NSCLC had high flux through and dependence on the hexosamine biosynthesis pathway.
H3.3G34R/V-mutant high-grade gliomas became reliant on activating PDGFRA mutations for maintenance.
Age, status of cancer treatment, and cancer prognosis can determine how patients will fare.
MHC-I and MHC-II regulators in lymphomas, some of which had subtype or tumor specificity, were identified.
OnlineFirst articles are published online before they appear in a regular issue of the journal. Cancer Discovery publishes two types of OnlineFirst articles.
OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.
Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.
Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.
When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).
While an article is OnlineFirst, it may be cited as shown in the following example:
Elizabeth A. Platz et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment (April 1, 2011) Cancer Discov, 10.1158/2159-8274.CD-10-0020.
Sign up to be notified each time OnlineFirst articles are posted in Cancer Discovery.